Hirotaki K, Tomizawa K, Kitou S, Jinno S, Moriya S, Fujisawa T
Adv Radiat Oncol. 2025; 10(3):101706.
PMID: 39911721
PMC: 11794065.
DOI: 10.1016/j.adro.2024.101706.
Hall J, Dance M, Huang B, Steele E, Nguyen L, Repka M
Adv Radiat Oncol. 2024; 9(10):101588.
PMID: 39263446
PMC: 11387223.
DOI: 10.1016/j.adro.2024.101588.
Nagano T, Matsuya Y, Kaida A, Nojima H, Furuta T, Sato K
J Radiat Res. 2024; 65(5):628-639.
PMID: 39174316
PMC: 11420842.
DOI: 10.1093/jrr/rrae062.
Rykkelid A, Sinha P, Folefac C, Horsman M, Sorensen B, Soland T
Sci Rep. 2024; 14(1):11569.
PMID: 38773258
PMC: 11109162.
DOI: 10.1038/s41598-024-62272-z.
Jovanovic N, Palma D, Warner A, Mitchell S, Doyle P, Theurer J
Adv Radiat Oncol. 2024; 9(6):101484.
PMID: 38681896
PMC: 11043844.
DOI: 10.1016/j.adro.2024.101484.
Determining the library size for the optimal output plan in the RapidPlan knowledge-based planning system using multicriteria optimization.
Biswal S, Sarkar B, Goyal M
Br J Radiol. 2024; 97(1158):1153-1161.
PMID: 38637944
PMC: 11135798.
DOI: 10.1093/bjr/tqae084.
Long-Term Outcomes of Endoscopic Resection versus Open Surgery for Locally Advanced Sinonasal Malignancies in Combination with Radiotherapy.
Liu Q, Huang X, Chen X, Zhang J, Wang J, Qu Y
J Neurol Surg B Skull Base. 2024; 85(1):28-37.
PMID: 38274487
PMC: 10807958.
DOI: 10.1055/a-1980-8567.
Functionality of bone marrow mesenchymal stromal cells derived from head and neck cancer patients - A FDA-IND enabling study regarding MSC-based treatments for radiation-induced xerostomia.
Blitzer G, Paz C, Glassey A, Ganz O, Giri J, Pennati A
Radiother Oncol. 2024; 192:110093.
PMID: 38224919
PMC: 10922976.
DOI: 10.1016/j.radonc.2024.110093.
Gastrointestinal/genitourinary adverse event after intensity modulated versus three-dimensional primary radiation therapy in the treatment of prostate cancer: systematic review and meta-analysis.
Guo W, Sun Y, Zhang L, Yin X
J Cancer. 2023; 14(15):2878-2888.
PMID: 37781069
PMC: 10539562.
DOI: 10.7150/jca.87626.
Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomia.
Blitzer G, Glazer T, Burr A, Gustafson S, Ganz O, Meyers R
Cytotherapy. 2023; 25(11):1139-1144.
PMID: 37589639
PMC: 10615723.
DOI: 10.1016/j.jcyt.2023.07.009.
Assessment of dosimetric impact of interfractional 6D setup error in tongue cancer treated with IMRT and VMAT using daily kV-CBCT.
Shinde P, Jadhav A, Shankar V, Dhoble S
Rep Pract Oncol Radiother. 2023; 28(2):224-240.
PMID: 37456705
PMC: 10348325.
DOI: 10.5603/RPOR.a2023.0020.
Topical non-steroidal agents for the prevention of radiation dermatitis: a systematic review and meta-analysis.
Fatima S, Hirakawa S, Marta G, Caini S, Beveridge M, Bonomo P
Support Care Cancer. 2023; 31(4):217.
PMID: 36928164
DOI: 10.1007/s00520-023-07677-8.
Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.
Rosado M, Pioli C
Cancers (Basel). 2023; 15(4).
PMID: 36831435
PMC: 9954050.
DOI: 10.3390/cancers15041093.
Radiation Therapy Treatment Outcomes for Patients with Head and Neck Cancer: a Tertiary Care Centre Experience in a Tier Three Town.
Amina B, Anshul S, Sharan T, Anusha R, Lewis S, Umesh V
Indian J Otolaryngol Head Neck Surg. 2023; 74(Suppl 3):6146-6150.
PMID: 36742778
PMC: 9895132.
DOI: 10.1007/s12070-021-02810-7.
Impact of upgraded radiotherapy system on outcomes in postoperative head and neck squamous cell carcinoma patients.
Koiwai K, Hirasawa D, Sugimura M, Endo Y, Mizuhata K, Ina H
Rep Pract Oncol Radiother. 2023; 27(6):954-962.
PMID: 36632299
PMC: 9826660.
DOI: 10.5603/RPOR.a2022.0120.
Quality assurance assessment of intra-acquisition diffusion-weighted and T2-weighted magnetic resonance imaging registration and contour propagation for head and neck cancer radiotherapy.
Naser M, Wahid K, Ahmed S, Salama V, Dede C, Edwards B
Med Phys. 2022; 50(4):2089-2099.
PMID: 36519973
PMC: 10121748.
DOI: 10.1002/mp.16128.
Sarcopenia in head and neck cancer: A scoping review.
Jovanovic N, Chinnery T, Mattonen S, Palma D, Doyle P, Theurer J
PLoS One. 2022; 17(11):e0278135.
PMID: 36441690
PMC: 9704631.
DOI: 10.1371/journal.pone.0278135.
Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy.
Huynh T, Aass H, Falk R, Astrup G, Helland A, Bjoro T
J Cancer Surviv. 2022; 17(4):1082-1093.
PMID: 36350483
PMC: 9643919.
DOI: 10.1007/s11764-022-01273-1.
The impact of sarcopenia on survival and treatment tolerance in patients with head and neck cancer treated with chemoradiotherapy.
Bentahila R, Giraud P, Decazes P, Kreps S, Nay P, Chatain A
Cancer Med. 2022; 12(4):4170-4183.
PMID: 36263581
PMC: 9972161.
DOI: 10.1002/cam4.5278.
[AZD9291 suppresses proliferation and migration of nasopharyngeal carcinoma cells by inhibiting the PI3K-AKT-mTOR pathway].
Zhang H, Pang J, Zhang Y, Ma Y, Fan F, Liu H
Nan Fang Yi Ke Da Xue Xue Bao. 2022; 42(9):1403-1409.
PMID: 36210715
PMC: 9550546.
DOI: 10.12122/j.issn.1673-4254.2022.09.18.